Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

Autor: Yao, James C, Fazio, Nicola, Singh, Simron, Buzzoni, Roberto, Carnaghi, Carlo, Wolin, Edward, Tomasek, Jiri, Raderer, Markus, Lahner, Harald, Voi, Maurizio, Pacaud, Lida Bubuteishvili, Rouyrre, Nicolas, Sachs, Carolin, Valle, Juan W, Fave, Gianfranco Delle, Van Cutsem, Eric, Tesselaar, Margot, Shimada, Yasuhiro, Oh, Do-Youn, Strosberg, Jonathan, Kulke, Matthew H, Pavel, Marianne E

Publikováno v: In The Lancet 5-11 March 2016 387(10022):968-977

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Health-related quality of life in patients with advanced, nonfunctional, well-differentiated gastrointestinal or lung neuroendocrine tumors with everolimus vs. placebo in the phase 3, randomized, RADIANT-4 trial

Autor: Pavel, Marianne E, Singh, Simron, Strosberg, Jonathan, Pacaud, Lida Bubuteishvili, Degtyarev, Evgeny, Neary, MP, Carnaghi, Carlo, Tomasek, Jiri, Wolin, Edward, Raderer, Markus, Lahner, Harald, Valle, Juan, Pommier, Rodney, Cutsem, Eric Van, Tesselaar, M.E.T, Fave, Gianfranco Delle, Buzzoni, Roberto, Hunger, Matthias, Eriksson, Jennifer, Cella, David, Ricci, Jean-François, Fazio, Nicola, Kulke, Matthew H, Yao, James C

Publikováno v: Pavel, M E, Singh, S, Strosberg, J, Pacaud, L B, Degtyarev, E, Neary, MP, Carnaghi, C, Tomasek, J, Wolin, E, Raderer, M, Lahner, H, Valle, J, Pommier, R, Cutsem, E V, Tesselaar, M E T, Fave, G D, Buzzoni, R, Hunger, M, Eriksson, J, Cella, D, Ricci, J-F, Fazio, N, Kulke, M H & Yao, J C 2017, ' Health-related quality of life in patients with advanced, nonfunctional, well-differentiated gastrointestinal or lung neuroendocrine tumors with everolimus vs. placebo in the phase 3, randomized, RADIANT-4 trial ', The Lancet Oncology . https://doi.org/10.1016/S1470-2045(17)30471-0

BACKGROUNDIn the phase 3 RADIANT-4 trial, everolimus improved progression-free survival (PFS) vs. placebo in 302 patients with advanced, progressive, nonfunctional, well-differentiated gastrointestinal (GI) or lung neuroendocrine tumors (NET). We now

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3818::2ef1cc22d3f40c813359ff6b936a0c07
https://research.manchester.ac.uk/en/publications/fd5b73e8-c003-45c1-a25a-b17b83fb5281